RBM, SMA Foundation collaborate to develop plasma protein biomarkers for spinal muscular atrophy

The Spinal Muscular Atrophy (SMA) Foundation and Rules-Based Medicine, Inc. (RBM) announced today that they have reached the first milestone in a program to develop a panel of plasma protein biomarkers for SMA using RBM's Multi-Analyte Profiling (MAP) technology platform.  In this collaboration, RBM will discover and also confirm plasma protein biomarker candidates previously identified from the multicenter Biomarkers for SMA (BforSMA) clinical study sponsored by the SMA Foundation and conducted by BG Medicine. The identification of such biomarkers may help to assess drug efficacy and shorten the duration of clinical trials of SMA therapies.

In this initial stage of the collaboration, the SMA Foundation provided BforSMA plasma samples to RBM for processing on the DiscoveryMAP™ platform plus an additional set of 70 biomarker assays.  Candidate biomarkers were found that significantly differentiated between disease and control groups and correlated with SMA disease severity.  The SMA Foundation and RBM are continuing to analyze these results and plan to create a specific panel of biomarker assays for use in clinical trials exploring new treatments for SMA.

"Biomarkers are critical to accelerating therapeutic development for any disease. They are even more important for rare diseases like SMA where patient populations are small and mostly consist of children," said Karen Chen, Ph.D., Chief Scientific Officer of the SMA Foundation. "We are excited to work with RBM to leverage their MAP technology to develop a biomarker panel for SMA that will help evaluate responses to treatments more efficiently and minimize the burden of clinical trials for patients and families."

"We are delighted to support the efforts of the SMA Foundation to develop better treatments for this tragic disease," said Craig Benson, Chief Executive Officer of RBM.  "Our MAP technology has been effective as part of many therapeutic development programs and for identifying biomarker patterns linked to complex diseases.  The confirmation and validation of biomarker patterns on our platform and the availability of testing services through our CLIA-certified lab will accelerate the development of new treatments for SMA."

SOURCE Spinal Muscular Atrophy Foundation; Rules-Based Medicine, Inc

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Brain protein mutation from an autistic person alters behavior in mice